$HELP

So Eric H. L. purchased $1.1M of HELP

So Eric H. L. (Executive Chair) purchased 95,000 shares of CYBIN INC. (HELP) at $11.80 ($1.12M total) on 2026-09-01.

Original reporting
SEC EDGAR · So Eric H. L.
Published Sep 9, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
high confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishMed
01

Why it matters

The purchase adds to the insider's already sizable holding, reinforcing confidence in the company's strategy.

02

Market read

Large insider buy may attract short‑term buying interest and support the stock price.

03

What to watch

Potential upcoming clinical trial data or regulatory milestones not disclosed could be driving the purchase.

Relevance 7/10Novelty 7/10Timing: filed 2026-09-09, immediate market impact

Background

Form 4 filings are primary disclosures of insider transactions required by the SEC.

Company-level read

Ticker impact

$HELPBullishHigh confidence
Context

Executive Chair So Eric H. L. purchased 95,000 shares of Cybin Inc. (HELP) for $1.12M, increasing his stake to over 4.2 million shares.

Expected impact

Potential short‑term upside as market digests the large insider purchase.

Evidence & confidence

The purchase size ($1.1M) is material for a mid‑cap biotech and the buyer holds a senior executive role, indicating strong insider conviction.

Market effects

May boost sentiment toward biotech and pharma stocks as insider confidence is perceived positively.

Limited to U.S. biotech sector; no broader regional effect.

Minimal global impact beyond investors tracking Cybin.

Counterpoint

Insider buying could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Cybin Inc.

    Biopharmaceutical company developing psychedelic therapeutics.

  • So Eric H. L.

    Executive Chair of Cybin Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.